{
    "type": "ETN",
    "ucits": false,
    "replication_method": "synthetic",
    "leverage": false,
    "derivatives": true,
    "swaps": true,
    "inverse": false,
    "complex_factors": [
        "Synthetic replication via swap agreements",
        "Counterparty risk exposure",
        "Complex underlying index (UBS CMCI Zinc USD TR Index)",
        "No capital protection",
        "Issuer credit risk",
        "Structured exercise and redemption features"
    ],
    "classification": "complex",
    "supporting_data": "The product is an Open End Tracker Certificate (ETN) issued by UBS AG, not a UCITS fund, and does not represent ownership of underlying assets but a contractual claim on the issuer. The replication method is synthetic, relying on swap agreements to track the UBS CMCI Zinc USD TR Index, which is a commodity index with inherent complexity. The KIID explicitly states the product is 'not simple and may be difficult to understand,' and highlights significant counterparty risk, including issuer insolvency risk and potential total loss of capital. There is no capital protection, and the product includes structured exercise and redemption mechanisms with a multiplier and management fee adjustments. The risk indicator is medium-high (5/7), and the product requires advanced investor knowledge. The product does not use leverage or inverse exposure but involves derivative instruments inherently as part of its structure, not merely for risk management. The complexity is further supported by the product being a debt instrument with exposure to issuer credit risk and the synthetic replication via swaps, which are unfunded and expose investors to counterparty risk. The product\u2019s complexity is also indicated by the lack of physical replication, the structured nature of redemption, and the complexity of the underlying commodity index, which may involve roll costs and contango effects typical of commodity indices. These factors combined lead to a classification as a complex financial instrument under MiFID II."
}